Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells

Journal of Immunology

Volumn 166, Issue 9, 2001, Pages 5398-5406

  Gabrilovich, D I ^a   Velders, M P ^a   Sotomayor, E M ^a   Kast, W M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER IMMUNOLOGY; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL SEPARATION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR IMMUNOLOGY;

EID: 0035339932     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.9.5398     Document Type: Article

References (35)

1. T cell recognition of human tumors: Implication for molecular immunotherapy of cancer
2. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2 secreting tumors
3. Immunosuppressive factors in human cancer
4. Involvement of nitric oxide in bone marrow-derived natural suppressor activity
5. + cells within human head and neck squamous cell carcinomas
6. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors
7. Clinical significance of defective dendritic cell differentiation in cancer
8. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer
9. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 chain of T-cell receptor complex and antigen-specific T-cell responses
10. + cells
11. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation
12. + single positive cells with a class II major histocompatibility complex-restricted receptor
13. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
14. + T cells
15. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
16. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors
17. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
18. + T-cell tolerance to T-cell priming through in vivo ligation of CD40
19. Nitric oxide and macrophage function
20. Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction
21. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
22. All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia
23. Acute promyelocytic leukemia
24. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses
25. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
26. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide
27. IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer
28. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid
29. Detection of leukemic clone maturation in vivo by premature chromosome condensation
30. + BM cells
31. Retinoic acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells
32. Modulation of growth factor receptors Oh acute myeloblastic leukemia cells by retinoic acid
33. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
34. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor
35. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine